Sagimet Biosciences Inc. (SGMT)

Market Cap	177.76M
Revenue (ttm)	2.00M
Net Income (ttm)	-29.25M
Shares Out	31.91M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,445,899
Open	5.41
Previous Close	5.41
Day's Range	5.23 - 5.99
52-Week Range	2.13 - 20.71
Beta	n/a
Analysts	Buy
Price Target	24.00 (+330.88%)
Earnings Date	Nov 11, 2024

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMT
• Website: https://www.sagimet.com

Analyst Forecast

According to 4 analysts, the average rating for SGMT stock is "Buy." The 12-month stock price forecast is $24.0, which is an increase of 330.88% from the latest price.

Price Target

$24.0

(330.88% upside)

Analyst Consensus: Buy